MediWound

MediWound Ltd. is a biopharmaceutical company, which engages in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Its product is NexoBrid. The company was founded by Lior Rosenberg and Marian Gorecki in January 2000 and is headquartered in Yavne, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

MediWound reports $5M revenue, advances trials and manufacturing capacity

MediWound's Q1 2024 performance reflects solid revenue from NexoBrid, progress on manufacturing, and strategic advancements in clinical trials and FDA interactions.
While facing challenges in profitability and operational expenses, the company's strengths in innovation, market acceptance, and growth opportunities position it for future success.
With a focus on operational excellence and expansion plans, MediWound remains well-positioned to capitalize on market opportunities and drive sustainable growth.

MediWound reports revenue growth but faces profit challenges in Q2 2024

MediWound's Q2 2024 performance showed revenue growth but faced challenges with decreased gross profit and increased losses. Despite liquidity concerns, the company is capitalizing on opportunities in NexoBrid and EscharEx developments. Analyst interest in capacity expansion and trial funding indicates market potential.

MediWound reports Q3 revenue, faces revenue challenges, eyes growth opportunities

MediWound's financial performance in Q3 2024 showed revenue and profit figures.
Strengths include regulatory approvals, facility expansion, and significant investments.
Challenges lie in revenue projections, capacity constraints, and financial losses.
Opportunities exist in upcoming studies, events, and funding for product development.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MediWound Ltd. is a biopharmaceutical company, which engages in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Its product NexoBrid, is an orphan biologic for eschar removal in severe burns. The company was founded by Lior Rosenberg and Marian Gorecki in January 2000 and is headquartered in Yavne, Israel.

YAVNE, Israel, Jan. 05, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that it will participate in the forthcoming LifeSci Partners 10th Annual Corporate Access Event and the H.C. Wainwright BioConnect 2021 Conference. Both conferences will take place virtually.

MediWound to Participate in Upcoming Investor Conferences in January

MediWound recently reported an encouraging Q3 with a beat on EPS and revenue. It looks as if the company is easily weathering the pandemic with support from BARDA purchases. I have already established a speculative position ahead of a potential NexoBrid approval. Now, I am looking to stick my MDWD in the back of my sock drawer.

MediWound: A Collectable Investment Worthy Of A Long-Term Hold

Data to be Published in a Peer-Reviewed Journal in First Half 2021 Data to be Published in a Peer-Reviewed Journal in First Half 2021

Successful Completion of In-Vivo Head-to-Head Comparator Study of EscharEx versus a Commercial Enzymatic Debridement Agent

YAVNE, Israel, Dec. 14, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced it has further expanded its NexoBrid® global presence and entered the Middle Eastern markets with the signing of a distribution agreement granting Ghassan Aboud Group (GAG), an international conglomerate based in the United Arab Emirates (UAE), an exclusive right to market and distribute NexoBrid in UAE for the treatment of severe burns. Commercialization of NexoBrid in the UAE will commence upon securing regulatory approval, which is expected within a year.

MediWound Continues Global Expansion with Distribution Agreement for NexoBrid in United Arab Emirates with Ghassan Aboud Group

MediWound Ltd. (MDWD) CEO Sharon Malka on Q3 2020 Results - Earnings Call Transcript

Shares of MediWound (NASDAQ:MDWD) remained unaffected after the company reported Q3 results. Quarterly Results Earnings per share rose 36.36% over the past year to ($0.07), which beat the estimate of ($0.10).

MediWound: Q3 Earnings Insights

Total Third Quarter R evenues of $6.6 Million Increased 29 % Y ear-over- Y ear

MediWound Reports Third Quarter 2020 Financial Results

MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will MediWound (MDWD) Report Negative Earnings Next Week? What You Should Know

YAVNE, Israel, Nov. 02, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release its financial results for the third quarter ended September 30, 2020 at 7:00 am Eastern Time on Tuesday, November 10, 2020.

MediWound to Report Third Quarter 2020 Financial Results and Host a Conference Call and Webcast on November 10, 2020

Top-line Data is Expected in the Second Half of 2021 Top-line Data is Expected in the Second Half of 2021

MediWound Completes Enrollment Stage of its NexoBrid Phase 3 Pediatric Study

Bromelain Degradation of Biofilms Could Provide Clinically Meaningful Benefits in Wound Healing Bromelain Degradation of Biofilms Could Provide Clinically Meaningful Benefits in Wound Healing

MediWound Studying the Effect of EscharEx on Biofilm Burden

YAVNE, Israel, Sept.  16, 2020  (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “MediWound”), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its recently submitted Biologics License Application (BLA) for NexoBrid® for eschar removal (debridement) in adults with deep partial-thickness and/or full-thickness thermal burns.  The FDA assigned a Prescription Drug User Fee Act (PDUFA) target date of June 29, 2021.  In addition, the FDA communicated that it is not currently planning to hold an advisory committee meeting to discuss the application.

MediWound Announces FDA Acceptance of Biologics License Application for NexoBrid for the Treatment of Severe Thermal Burns

MediWound: An Underfollowed Opportunity At A Discount

YAVNE, Israel, Sept.  03, 2020  (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that Sharon Malka, MediWound’s Chief Executive Officer, will present at the following investor conferences in September:

MediWound to Present at Upcoming Investor Conferences in September

Vericel

YAVNE, Israel and CAMBRIDGE, Mass., Aug.  25, 2020  (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD) and its U.S. commercial partner Vericel Corporation (NASDAQ: VCEL) today announced that the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services, has accepted the first shipment of NexoBrid® (concentrate of proteolytic enzymes enriched in Bromelain) as part of its mission to build national preparedness for public health emergencies. The initial BARDA procurement of NexoBrid is valued at $16.5 million, which includes additional quarterly deliveries planned through the end of 2021. In addition, BARDA holds an option to procure additional quantities of NexoBrid through funding of up to $50 million.

MediWound and Vericel Announce Acceptance of the First Delivery of NexoBrid to BARDA for Emergency Response Preparedness

Mediwound Ltd (MDWD) CEO Sharon Malka on Q2 2020 Results - Earnings Call Transcript

Submitted Biological License Application to the FDA for NexoBrid  EscharEx U.S. Phase 2 Study Resumed Patient Screening

MediWound Reports Second Quarter 2020 Financial Results and Provides Corporate Update

YAVNE, Israel, July  28, 2020  (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release its financial results for the second quarter ended June 30, 2020 at 7:00 am Eastern Time on Thursday, August 6, 2020.

MediWound to Report Second Quarter 2020 Financial Results and Host a Conference Call and Webcast on August 6, 2020

MediWound (MDWD) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

MediWound (MDWD) Jumps: Stock Rises 9.4%

YAVNE, Israel, June  30, 2020  (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet medical needs in severe burn and wound management, today announced it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking the approval of NexoBrid® for eschar removal (debridement) in adults with deep partial-thickness and/or full-thickness thermal burns. 

MediWound Announces Submission of Biologics License Application to the U.S. FDA for NexoBrid for the Treatment of Severe Thermal Burns

Mediwound, An Attractive Opportunity Through The Coronavirus Crisis

MediWound Ltd (MDWD) CEO Sharon Malka on Q1 2020 Results - Earnings Call Transcript

Shares of MediWound (NASDAQ:MDWD) moved higher by 6% in pre-market trading after the company reported Q1 results.

Recap: MediWound Q1 Earnings

EscharEx U.S. Phase 2 Study Resumed Patient Screening EscharEx U.S. Phase 2 Study Resumed Patient Screening

News for MediWound Stock (MDWD)